MedTrace Logo

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC945

NCT02715570 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2018-05-01

No results posted yet for this study

Summary

PC945 is a new medicine being developed for treatment of fungal lung diseases. The main purpose of this study is to investigate the safety, tolerability and pharmacokinetics of single and repeat doses of PC945

Conditions

  • Aspergillosis

Interventions

DRUG

PC945 - single doses

Safety and tolerability of single doses

DRUG

Placebo - single doses

Safety and tolerability of single doses

DRUG

PC945 - repeat doses

Safety and tolerability of repeat doses

DRUG

Placebo - repeat doses

Safety and tolerability of repeat doses

Sponsors & Collaborators

  • Pulmocide Ltd

    lead INDUSTRY

Principal Investigators

  • Muna Albayaty, MBChB, FFPM, MSc · cro

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-10-23
Primary Completion
2018-04-27
Completion
2018-04-27

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02715570 on ClinicalTrials.gov